The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
POLARIX: 5-year follow-up of Pola-R-CHP in patients with intermediate- or high-risk DLBCL
|
Pola, an antibody–drug conjugate targeting CD79b, was approved by the FDA in combination with R-CHP for the treatment of patients with untreated DLBCL based on results from the POLARIX trial (NCT03274492). POLARIX is a phase III, randomized trial that investigated the efficacy and safety of Pola in combination with R-CHP (Pola-R-CHP; ITT, n = 500; safety evaluable, n = 495) vs standard of care (R-CHOP; ITT, n = 500; safety evaluable, n = 498) as first-line treatment for patients with DLBCL. The Lymphoma Hub has previously covered the primary results, descriptive analysis outcomes, safety and efficacy in elderly patients, Asian population analysis, and Pola-R-CHP vs R-CHOEP outcomes from the trial. Here, we summarize the 5-years results presented at the 66th ASH Annual Meeting and Exposition by Gilles Salles.1 |
| Key learnings |
| At the 5-year follow-up, PFS remained significantly improved with Pola-R-CHP vs R-CHOP (64.9% vs 59.1%). |
| The 5-year DFS and OS rates were also higher with Pola-R-CHP vs R-CHOP at 71.8 vs 66.5% and 82.3% vs 79.5%, respectively. |
| The safety profiles of Pola-R-CHP and R-CHOP were comparable, with similar rates of any grade and Grade 3–5 AEs, including any grade peripheral neuropathy (50.3% vs 52.4%) and infections (47.9% vs 44.0%). The difference in hematologic toxicities was <5% between arms. |
| Long-term data from the POLARIX trial demonstrate deep and durable efficacy of Pola-R-CHP, with sustained and significant PFS and DFS benefits vs R-CHOP and a comparable safety profile, supporting its use in patients with intermediate- or high-risk untreated DLBCL. |
Abbreviations: AE, adverse event; DLBCL, diffuse large B-cell lymphoma; DFS, disease-free survival; FDA, U.S. Food and Drug Administration; ITT, intention to treat; OS, overall survival; PFS, progression-free survival; Pola-R-CHP, polatuzumab vedotin-rituximab-cyclophosphamide-doxorubicin-prednisone; R-CHOP, rituximab-cyclophosphamide-doxorubicin-vincristine-and prednisone.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
